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Abstract 
 Malaria is a parasite disease that is endemic in tropical country as 
Niger (West Africa). Hydroxychloroquine sulfate (HCQ) is a synthetic anti-
malarial drug that is very often used to treat connective tissue diseases such 
as, scleroderma, systemic or discoid lupus erythematosus, rheumatoid 
arthritis. This drug may induce numerous cutaneous adverse reactions as 
well as the other anti-malarial drugs. We report on a case of intermediate 
Lyell syndrome that occurred in the first week of treatment of malaria attack 
with a young woman, aged 19, following the administration of 
hydroxychloroquine sulfate. 
 
Keywords: Hydroxychloroquine sulfate, intermediate Lyell syndrome, 
malaria 
 
Introduction 
 Lyell syndrome is a form of toxic epidermal necrolysis (TEN) that 
can be induced by certain drugs (Roujeau et al., 1995; Bechot et al., 2000; 
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Bernard et al., 2010). It is well known that any drug can cause an adverse 
reaction that can occur from a few days to several weeks, during or after 
administration (Bernard et al., 2010; Studer et al., 2012). HCQ is a synthetic 
antimalarial drug rarely known to induce toxidermia of the TEN type. We 
report on a case of intermediate Lyell's syndrome induced by 
hydroxychloroquine sulfate in a young woman, aged 19, during a malaria 
treatment. 
 
Observation 
 The patient, a 19-year-old young woman, presented a dorsolumbar 
epidermal detachment. Under questioning, she declared that the detachment 
was preceded by a generalized but intense pruritus in the same area. She also 
disclosed having taken hydroxychloroquine sulfate alone for the treatment of 
a malaria, following a positive blood smears test. In the first week of 
treatment, a generalized pruritus occurred, followed by the appearance of 
purplish blotches at the upper dorsal area and traveling down the lumbar 
spine. The epidermal detachment proper followed within 48 hours. A 
physical examination of the patient revealed a more extensive dorsolumbar 
epidermal peel off at the dorsal area stretching to the lumbar spine and 
exposing the underlying dermis (Figure 1). The lesion was very painful, 
moist and slightly purulent. A Nikolsky sign check turned out negative on 
the rest of the body. There was also a related small skin detachment on the 
posterior side of the middle third area of the right arm. All mucosas were 
free of lesions. An anatomopathological analysis of a biopsy sample from the 
dorsal surface of the right arm evidenced the conventional attacks: epidermal 
necrolysis with a dermal inflammatory infiltrate containing lymphocytes and 
red cells in bullous lesion (Figure2). Biologically, we noted no anomalies 
(especially with the liver or kidneys), except an hyperleukocytosis (12300) 
that mostly involved polynuclear neutrophils (70%). Local care    was 
prescribed with an antibiotic cover (macrolide) after excluding the possibility 
of their involvement. During a two-week follow up, we noticed that the 
epidermization was going on normally (Figure 3A, 2B); however, we lost 
sight of the patient after this period. 
 
Figure 1: Epidermal detachment at the dorsolumbar area,             Figure2 Fig3: X100 Distinct epidermal necrolysis, 
with an onset of super infection,     with a   dermal inflammatory infiltrate  dermal                
                                                                                                            containing  lymphocytes and red cells.                                                                                             
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A: One week after treatment                                                   B: Two weeks after treatment 
Fig3(A and B): Drying and epidermization of the skin at the dorsolumbar area and the right 
arm’s posterior side. 
      
Discussion 
 TEN is a drug-induced bullous toxidermia that destroys the skin and 
the mucosas (Lebrun-Vignes et al., 2015). The method of Begaud et al 
(Begaud et al., 1985), used to determine the source of unexpected or toxic 
effects of drugs, most often allows the identification of the drug causing the 
ailment. In our case, the identification of the drug in question was not 
difficult, since HCQ was the only molecule taken by the patient for her 
malaria treatment. Generally, as is true in our case, TEN occurs 1 to 4 weeks 
after the administration of the drug (Lebrun-Vignes et al., 2015). HCQ is a 
synthetic antimalarial drug whose side effects, as reported by various 
authors, are: Severe Acute Generalized Exanthematous Pustulosis (AGEP) 
(Naziha et al., 2010; Assier-Bonnet et al., 1996; Park et al., 2010), photo-
induced toxidermia (Metayer et al., 2001), Drug Rash with Eosinophilia and 
Systemic Symptoms (DRESS) (Schmutz et al., 2008), and TEN (Plaquenil 
(hydroxychloroquine sulphate) tablets; 2006). Cases of Lyell syndrome are 
rare. Based on the size of the affected area, various types of TEN are 
distinguished: The Stevens Johnson syndrome (affected area is less than 10% 
of body surface), the overlapping or intermediate Lyell syndrome (affected 
area between 10 and 30%), and the full Lyell syndrome (affected area above 
30%) (Roujeau et al., 1995; Parveen et al., 2014; Paquet et al., 2004). In the 
case of our patient, the affected area was between 10 and 30% of the body 
surface, which corresponds to the intermediate form. The 
anatomopathological analysis only showed the typical skin alterations. For 
example, the skin biopsy revealed a deep necrosis of the epidermis, which 
was detached from a more or less intact dermis, with a barely noticeable 
lymphocytic infiltrate. (Paquet et al., 2004). Although bullous toxidermia are 
frequently reported to have multiple biological attacks (Ho et al. 2010), the 
assessment performed on our patient revealed only a hyperleukocytosis that 
mostly involved polynuclear neutrophils. The rapid epidermization coupled 
with a repigmentation during the treatment, pointed to a rather shallow 
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damage to the skin. Such shallow damages heal most often through 
epidermization from adjacent areas (Barbaud, 2007). As many authors report 
(Naziha et al., 2010; Barbaud, 2007), the withdrawal of the drug and a 
detailed letter prohibiting it once and for all should be systematic upon 
patient discharge. Unfortunately, we could not take these steps given the fact 
that the patient never came back after a two-week follow-up. 
 
Conclusion 
 Toxidermia of the Lyell syndrome type are rarely associated with 
drugs families. HCQ, used in the treatment of certain so-called autoimmune 
diseases, has rather variable cutaneous side effects. Despite the rare 
occurrence of these reactions, it is important to inform the patient to seek 
medical attention at the slightest effect in the skin or mucous membranes. A 
medical certificate specifying the drug concerned must be established and 
given to the patient. 
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